PDCD1 and head and neck squamous cell carcinoma: In 2016, both pembrolizumab and nivolumab were approved for the treatment of R/M HNSCC after platinum-based chemotherapy based on KEYNOTE-040 and CHECKMATE-141 studies, respectively, which demonstrated the survival benefit of anti-PD-1 therapy compared to standard chemotherapy [9,10].